Patients with disorders of hemostasis are subject to long term problems and risks, difficult treatment decisions and risks associated with treatment itself. Many of these risks and complications can be lessened or prevented by appropriate intervention strategies. Advances in the management of patients with bleeding disorders and those requiring transfusions require: 1) that clinical studies utilize a multi-institutional cooperative network in order to accrue sufficient numbers of patients to achieve meaningful answers;and 2) that patients receive specialized clinical care while participating in such trials. The Transfusion Medicine/Hemostasis (TMH) Clinical Trials Network was initiated in October, 2002. Tulane University Health Sciences Center is one of the 17 core sites that comprise the clinical trials network. The Tulane core site was developed using the basic infrastructure and services of the Louisiana Center for Bleeding and Clotting Disorders which cares for over 400 patients with disorders of hemostasis, and serves a role in the accrual of patients with bleeding disorders as well as in their clinical care .while participating in clinical trials. In addition, the Tulane Bone Marrow Transplant Unit plays an important role in the implementation of transfusion medicine trials at the Tulane site. The PI and Co-Pi's from the Tulane site have played an integral role in the development of the network during it's initial 5 year period, and in the development and implementation of network studies. The purpose of this project at the Tulane site is to continue full participation in TMH network activities, both in the implementation of trials developed during the initial grant period as well as in the development of new protocols to be implemented in the network during the second 5 year award period.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1-CSR-J (M1))
Program Officer
Mondoro, Traci
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Tulane University
Internal Medicine/Medicine
Schools of Medicine
New Orleans
United States
Zip Code
Leissinger, C; Josephson, C D; Granger, S et al. (2014) Rituximab for treatment of inhibitors in haemophilia A. A Phase II study. Thromb Haemost 112:445-58
Triulzi, Darrell J; Assmann, Susan F; Strauss, Ronald G et al. (2012) The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. Blood 119:5553-62
Josephson, Cassandra D; Granger, Suzanne; Assmann, Susan F et al. (2012) Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia. Blood 120:748-60
Slichter, Sherrill J; Kaufman, Richard M; Assmann, Susan F et al. (2010) Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 362:600-13
Slichter, Sherrill J (2006) Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients. J Clin Apher 21:78-84
Searles, Charles D (2006) Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression. Am J Physiol Cell Physiol 291:C803-16
Kahn, Marc J; McCrae, Keith R (2004) Splenectomy in immune thrombocytopenic purpura: recent controversies and long-term outcomes. Curr Hematol Rep 3:317-23